Gilead: Strong Sales Growth Remains With Veklury And Beyond
Portfolio Pulse from
Gilead Sciences reports strong sales growth, particularly in Veklury due to increased Covid-19 hospitalizations. Q3 2024 sales rose by 9% to $692 million. LIVDELZI shows promise with FDA Accelerated Approval and potential EMA approval. TRODELVY sales increased by 17% with potential expansion into new cancer treatments.
February 03, 2025 | 10:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences reports a 9% increase in Q3 2024 sales of Veklury, driven by rising Covid-19 hospitalizations. LIVDELZI gains FDA Accelerated Approval, with potential EMA approval in Q1 2025. TRODELVY sales grow by 17%, with potential for new cancer treatment applications.
The increase in Veklury sales due to Covid-19 hospitalizations and the promising developments for LIVDELZI and TRODELVY suggest a positive outlook for Gilead Sciences. The FDA approval and potential EMA approval for LIVDELZI, along with the expansion of TRODELVY into new cancer treatments, indicate strong future growth potential.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100